Composition, form of production and packaging
Solution for intravenous administration 1 vial.
thallium-199 1850 MBq
[PRING] sodium chloride, water d / and.
1850 MBq - bottles (1) - a set of packaging transport.
Solution for intravenous administration 1 vial.
thallium-199 925 MBq
[PRING] sodium chloride, water d / and.
925 MBq - bottles (1) - a set of packing transport.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
PHARMACHOLOGIC EFFECT
Thallium-199, being a biological analogue of potassium, is actively accumulated by healthy cardiomyocytes, which allows using the planar scintigraphy or single-photon emission computed tomography to estimate the blood supply of the myocardium in various pathological processes leading to a violation of its perfusion.
PHARMACOKINETICS
Thallium-199 after intravenous administration quickly leaves the vascular bed and in 3-5 minutes its content in the circulating blood is no more than 4% of the administered amount.
The maximum accumulation of the drug in a healthy myocardium is observed at 6-8 minutes after the injection and is 4-5% of the administered dose. This level of myocardial capture remains unchanged for 30-35 minutes, which determines the optimal timing of planar scintigraphy or single-photon emission computed tomography, which is 6-10 minutes after intravenous administration of the drug
INDICATIONS
The drug is used in adults for the diagnosis of heart disease associated with a violation of its blood supply:
- coronary atherosclerosis;
- Transient myocardial ischemia;
- postinfarction cardiosclerosis;
myocardial infarction, etc.
DOSING MODE
When assessing the blood supply to the myocardium under stress test conditions and at rest with an interval of about 24 hours, the thallium-199 preparation is administered intravenously in an amount of 110-185 MBq per study.
Before the study, the gamma camera was tuned to a photopic radiation of 199 Tl (60-80 keV) with a differential discriminator window width of 20%; the study is recommended to be carried out using a high-energy (300 keV) parallel collimator.
After 6-10 minutes after the administration of the drug, planar (in three projections) scintigraphy or single-photon emission computed tomography (OECT) of the heart is performed. To determine the redistribution of the drug in the myocardium 2-3 hours after the injection, a second study (planar scintigraphy or OECT) is performed.
Radiation load on the organs and entire body of the patient with the use of the preparation Thallium chloride, 199 TI
Organs and systems Absorbed dose, ОјGy / MBq
Whole body 19
Gonads 33
Heart 32
The kidneys 44
SIDE EFFECT
There were no any side effects when using the drug for diagnostic purposes.
CONTRAINDICATIONS
Specific contraindications to the use of the drug there.
The use of thallium-199 is limited by general clinical contraindications to the use of radionuclide studies.
Contraindicated use of the drug during pregnancy.
Breastfeeding mothers should refrain from breastfeeding the baby within 24 hours after drug administration.
PREGNANCY AND LACTATION
Contraindicated use of the drug during pregnancy.
Breastfeeding mothers should refrain from breastfeeding the baby within 24 hours after drug administration.
DRUG INTERACTION
When conducting diagnostic studies, interaction with other drugs was not detected.
TERMS OF RELEASE FROM PHARMACY
It is only released on request to specialized radioisotope laboratories of medical diagnostic facilities.
TERMS AND CONDITIONS OF STORAGE
The drug is stored in accordance with the "Basic Sanitary Regulations for Ensuring Radiation Safety" (OSPORB-99). Shelf life of the drug is 14 hours from the established date and time of manufacture.
